Assisted reproductive technology (ART) is the fertility treatment in which surgically eggs are removed from the women ovaries and are combined with the sperms in the laboratory, further they are returned to the ovaries or are donated to another women. Whereas, ART does not include the treatment where only sperms are handled or pills are taken to stimulate the egg production. ART can be used to avoid the fertility problems while preserving the genetic connection. The world’s first test tube baby was born in 1978 in Britain and by 2012, about 1.5 million ART cycles were performed annually worldwide. However, 76.7% ART procedures failed and 23.3% were successful which leads to live birth. Hence, generally ART recommended when other treatments have not been successful and when there is several male infertility or tubal obstruction.
Assisted reproductive technology market can be segmented as in-vitro fertilization-embryo transfer (IVF-ET), zygote intrafallopian transfer (ZIFT), gamete intrafallopian transfer (GIFT), and frozen embryo transfer (FET) by procedure. In vitro fertilization-embryo transfer is the largest market segment due to its higher success rate, reimbursement policies, and introduction of new technology in IVF. In earlier days multiple sperms were injected to increase the success rate but presently, time lapse imaging system has been accepted where clear picture of egg division are recorded and fate of embryo has been decided.
For More info Click Here.